|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2019-12-20
|
|
gptkbp:ATCCode
|
gptkb:L01FG02
|
|
gptkbp:CASNumber
|
gptkb:2228327-56-2
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Daiichi_Sankyo
|
|
gptkbp:EMAApprovalDate
|
2021-01-18
|
|
gptkbp:form
|
intravenous infusion
lyophilized powder for solution
|
|
gptkbp:genericName
|
gptkb:trastuzumab_deruxtecan
|
|
gptkbp:hasBoxedWarning
|
interstitial lung disease
embryo-fetal toxicity
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Enhertu
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
gptkb:HER2-positive_breast_cancer
HER2-low breast cancer
HER2-positive gastric cancer
|
|
gptkbp:KEGGID
|
D11760
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:monoclonal_antibody
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297629
gptkb:DB15054
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
fatigue
neutropenia
interstitial lung disease
|
|
gptkbp:target
|
HER2
|
|
gptkbp:UNII
|
6Y7M6M9K3U
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_US
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
6
|